Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess feasibility, safety and preliminary efficacy of
Brentuximab vedotin (Adcetris), a CD30-directed antibody-drug conjugate, in the treatment of
active diffuse cutaneous systemic sclerosis (dcSSc).